Skip to main content

Peer Review reports

From: Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

Original Submission
28 Jun 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
17 Oct 2021 Reviewed Reviewer Report
15 Nov 2021 Reviewed Reviewer Report
7 Dec 2021 Author responded Author comments - Eva Martínez-Moragón
Resubmission - Version 3
7 Dec 2021 Submitted Manuscript version 3
Publishing
8 Dec 2021 Editorially accepted
18 Dec 2021 Article published 10.1186/s12890-021-01785-z

You can find further information about peer review here.

Back to article page